# Invanz - (1 g/vial; Injectable, Intramuscular, Intravenous)

| | | | |
|---|---|---|---|
| **Generic Name** | Ertapenem | **Innovator** | Merck |
| **Dosage** | 1 g/vial; Injectable, Intramuscular, Intravenous | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | Less Than 5 | **Known Para IV Filers** | Less Than 5 |
| **Other ANDA developers** | More Than 5 | **Tentative Approvals** | None |
| **Final Approvals** | More Than 5 | **Generic Launches** | Less Than 5 |
| **Indication** | Indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis caused by bacteria | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.